A Pilot Study of the Treatment of Central Serous Chorioretinopathy With Ketoconazole
Status:
Completed
Trial end date:
2008-04-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the effect of an adrenocorticoid antagonist
(ketoconazole), 600 mg per day for 4 weeks, in the treatment of patients with central serous
chorioretinopathy (CSC).